KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $21.0 million.

  • Recursion Pharmaceuticals' Depreciation & Amortization (CF) rose 19234.51% to $21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.2 million, marking a year-over-year increase of 14817.98%. This contributed to the annual value of $36.5 million for FY2024, which is 4955.33% up from last year.
  • Recursion Pharmaceuticals' Depreciation & Amortization (CF) amounted to $21.0 million in Q3 2025, which was up 19234.51% from $23.8 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $23.8 million during Q2 2025, and its lowest value of $1.4 million during Q1 2021.
  • Over the past 5 years, Recursion Pharmaceuticals' median Depreciation & Amortization (CF) value was $5.5 million (recorded in 2023), while the average stood at $7.6 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Depreciation & Amortization (CF) plummeted by 501.45% in 2024, and later soared by 19234.51% in 2025.
  • Recursion Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $2.2 million in 2021, then soared by 43.74% to $3.2 million in 2022, then skyrocketed by 135.0% to $7.6 million in 2023, then skyrocketed by 71.47% to $13.0 million in 2024, then surged by 62.48% to $21.0 million in 2025.
  • Its last three reported values are $21.0 million in Q3 2025, $23.8 million for Q2 2025, and $19.3 million during Q1 2025.